Given the novel uses of IL-Y, it is possible that synthetic combinations of the IL-27-IL-30-IL-35 cytokine subunits may be utilized to direct immune cell activities in the TME in novel immunotherapeutic cancer treatments targeted toward enhancing anti-tumor immune responses, while directly targeting the tumors themselves. This evidence concerns the gene IL27 and neoplasm.